<DOC>
	<DOCNO>NCT01178268</DOCNO>
	<brief_summary>This prospective , randomize , active-controlled , open label , parallel two-arm , multi-center , post-approval study descriptively compare XIENCE V EECSS CYPHER SELECT PLUS Sirolimus-Eluting Coronary Stent System ( SECSS ) ( `` CYPHER SELECT PLUS '' ) commercial use China .</brief_summary>
	<brief_title>XIENCE V Everolimus Eluting Coronary Stent System ( EECSS ) China : Post-Approval Randomized Control Trial ( RCT )</brief_title>
	<detailed_description>Objectives - Confirm safety effectiveness XIENCE V EECSS treatment patient China - Evaluate patient compliance dual antiplatelet therapy ( DAPT ) - Evaluate physician-determined XIENCE V EECSS acute performance , deliverability , resource utilization</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>General Inclusion Criteria 1 . Patient must least 18 year age 2 . The patient patient 's legallyauthorized representative agrees participate study sign Ethics Committee ( EC ) approve ICF prior procedure . 3 . Patient must agree undergo protocolrequired followup completion his/her 2year followup . 4 . Patient must currently must agree become participant clinical trial completion his/her 2year followup . Angiographic Inclusion Criteria 1 . Target lesion ( ) must locate native de novo coronary artery visually estimate diameter ≥ 2.25 ≤ 4.0 mm . 2 . Target lesion ( ) must measure ≤ 28 mm length visual estimation . 3 . A maximum two de novo lesion treat , ie , 1 . One lesion one vessel , OR 2 . One lesion two vessel , OR 3 . Two lesion one vessel General Exclusion Criteria 1 . Pregnant nursing patient plan pregnancy period 1 year post index procedure 2 . Patients know renal insufficiency failure ( eg , serum creatinine level &gt; 2.5 mg/dL , patient dialysis ) 3 . Patient MI within 72 hour creatine kinasemyocardial band isoenzyme ( CKMB ) return normal range index procedure 4 . Nonstudy PCI lesion target vessel ( include side branch ) perform within 1 year prior index procedure 5 . Patient plan PCI ( staged procedure ) within 6 month date index procedure 6 . Left ventricular ejection fraction ( LVEF ) &lt; 30 % . 7 . Any planned surgery necessitate discontinuation antiplatelet therapy within 1 year 8 . Patient 's current medical condition life expectancy &lt; 2 year 9 . Patient meet contraindication IFU Angiographic Exclusion Criteria 1 . Lesion locate within arterial saphenous vein graft distal diseased arterial saphenous vein graft 2 . Lesion locate leave main coronary artery 3 . Ostial lesion ( within 3 mm aorta junction , origin leave anterior descending leave circumflex artery ) 4 . Involves bifurcation side branch ≥ 2 mm diameter AND ostium side branch &gt; 50 % stenosed visual estimation 5 . Total occlude lesion ( TIMI=0 ) 6 . Restenotic lesion 7 . Thrombuscontaining vessel 8 . Extreme angulation ( ≥ 90º ) proximal within lesion 9 . Excessive tortuosity proximal within lesion 10 . Heavy calcification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug elute stent</keyword>
	<keyword>Stents</keyword>
	<keyword>Angioplasty</keyword>
</DOC>